Valuation: ImmunityBio, Inc.

Capitalization 8.35B 7.18B 6.57B 6.27B 11.49B 801B 11.68B 78.79B 30.49B 380B 31.33B 30.66B 1,325B P/E ratio 2026 *
-9.54x
P/E ratio 2027 * -99.6x
Enterprise value 8.35B 7.18B 6.57B 6.27B 11.49B 801B 11.68B 78.79B 30.49B 380B 31.33B 30.66B 1,325B EV / Sales 2026 *
36.3x
EV / Sales 2027 * 15.6x
Free-Float
37.52%
Yield 2026 *
-
Yield 2027 * -
1 day-2.21%
1 week-6.35%
Current month+12.25%
1 month+9.93%
3 months+34.06%
6 months+283.17%
Current year+302.53%
1 week 7.78
Extreme 7.78
8.69
1 month 6.73
Extreme 6.73
8.69
Current year 1.98
Extreme 1.98
12.43
1 year 1.95
Extreme 1.95
12.43
3 years 1.25
Extreme 1.25
12.43
5 years 1.21
Extreme 1.21
18.14
10 years 1.21
Extreme 1.21
40.83
Manager TitleAgeSince
Chief Executive Officer 57 2020-09-30
Chief Executive Officer 73 2015-02-28
Director of Finance/CFO 48 2021-02-28
Director TitleAgeSince
Director/Board Member 80 2021-01-31
Director/Board Member 71 2021-02-28
Chairman 73 2014-11-30
Change 5d. change 1-year change 3-years change Capi.($)
-2.21%-6.35%+180.63%+140.79% 8.35B
-0.14%+3.34%+37.43%+87.05% 50.1B
+0.12%-3.44%+68.07%+49.81% 45.82B
-5.60%+7.69%+60.22%+493.80% 23.66B
-2.65%-4.86%-3.47%-15.20% 22.65B
+3.19%+3.12%+43.01%-27.88% 17.8B
-1.66%+2.59%+27.48%-40.75% 16.08B
-2.91%-10.30%+43.95%+184.83% 14.14B
-7.00%-6.69%-29.33%+995.45% 13.09B
+0.41%-2.37%+35.93% - 13B
Average -1.84%-2.64%+46.39%+207.55% 22.47B
Weighted average by Cap. -1.38%-1.49%+43.44%+158.98%

Financials

2026 *2027 *
Net sales 230M 198M 181M 172M 316M 22.04B 321M 2.17B 839M 10.46B 862M 844M 36.46B 534M 460M 420M 401M 735M 51.27B 748M 5.04B 1.95B 24.34B 2.01B 1.96B 84.8B
Net income -864M -743M -680M -648M -1.19B -82.87B -1.21B -8.15B -3.15B -39.34B -3.24B -3.17B -137B -88M -75.73M -69.24M -66.06M -121M -8.44B -123M -831M -321M -4.01B -330M -323M -13.96B
Net Debt - -
Logo ImmunityBio, Inc.
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Employees
688
Date Price Change Volume
26-05-15 7.970 $ -2.21% 11,347,554
26-05-14 8.150 $ 0.00% 9,402,569
26-05-13 8.150 $ +0.37% 10,542,917
26-05-12 8.120 $ +0.12% 9,900,490
26-05-11 8.110 $ -4.70% 14,502,080
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
7.970USD
Average target price
15.25USD
Spread / Average Target
+91.34%

Quarterly revenue - Rate of surprise